Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor

Nature Medicine

Volumn 5, Issue 12, 1999, Pages 1390-1395

  Smith, Lois E H ^a   Shen, Wei ^a   Perruzzi, Carole ^b   Soker, Shay ^a   Kinose, Fumi ^a   Xu, Xianghong ^a   Robinson, Gregory ^a   Driver, Sam ^a   Bischoff, Joyce ^a   Zhang, Bei ^c   Schaeffer, James M ^c   Senger, Donald R ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIABETOGENESIS; DISEASE CONTROL; ENZYME ACTIVATION; INSULIN TREATMENT; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; REGULATORY MECHANISM; RETINA NEOVASCULARIZATION;

ANIMALS; ENDOTHELIAL GROWTH FACTORS; GROWTH INHIBITORS; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; ISCHEMIA; LYMPHOKINES; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, IGF TYPE 1; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETINAL VESSELS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032758384     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/70963     Document Type: Article

References (54)

1. Early treatment diabetic retinopathy study research group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 98, 766-785 (1991).
2. Zimmer-Galler, I.E., Bressler, N.M. & Bressler, S.B. Treatment of choroidal neovascularization: updated information from recent macular photocoagulation study group reports. Int. Ophthalmol. Clin. 35, 37-57 (1995).
3. Pierce, E.A., Foley, E.D. & Smith, L.E. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch. Ophthalmol. 114, 1219-1228 (1996); erratum: 115, 427 (1997).
4. Stone, J. et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J. Neurosci. 15, 4738-4747 (1995).
5. Stone, J. et al. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 37, 290-299 (1996).
6. Pierce, E.A., Avery, R.L., Foley, E.D., Aiello, L.P. & Smith, L.E. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. USA 92, 905-909 (1995).
7. Boulton, M., Foreman, D., Williams, C. & McLeod, D. VEGF localisation in diabetic retinopathy. Br. J. Ophthalmol. 82, 561-568 (1998).
8. Robinson, G.S. et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc. Natl. Acad. Sci. USA 93, 4851-4856 (1996).
9. Aiello, L.P. et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA 92, 10457-10461 (1995).
10. Borgstrom, P., Bourdon, M.A., Hillan, K.J., Sriramarao, P. & Ferrara, N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35, 1-10 (1998).
11. Ferrara, N. et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Med. 4, 336-340 (1998).
12. Smith, L.E. et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276, 1706-1709 (1997).
13. Sharp, P.S. et al. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 30, 199-207 (1987).
14. Merimee, T.J., Fineberg, S.E., McKusick, V.A. & Hall, J. Diabetes mellitus and sexual ateliotic dwarfism: a comparative study. J. Clin. Invest. 49, 1096-1102 (1970).
15. Wright, A.D. et al. Serum growth hormone levels and the response of diabetic retinopathy to pituitary ablation. Br. Med. J. 2, 346-348 (1969).
16. Sonksen, P.M., Russell-Jones, D. & Jones, R.H. Growth hormone and diabetes mellitus. A review of sixty-three years of medical research and a glimpse into the future? Horm. Res. 40, 68-79 (1993).
17. Merimee, T.J., Zapf, J. & Froesch, E.R. Insulin-like growth factors. Studies in diabetics with and without retinopathy. N. Engl. J. Med. 309, 527-530 (1983).
18. Amiel, S.A. et al. Effect of diabetes and its control on insulin-like growth factors in the young subject with type I diabetes. Diabetes 33, 1175-1179 (1984).
19. Grant, M., Russell, B., Fitzgerald, C. & Merimee, T.J. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes 35, 416-420 (1986).
20. Pfeiffer, A., Spranger, J., Meyer-Schwickerath, R. & Schatz, H. Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes 46, S26-30 (1997).
21. Meyer-Schwickerath, R. et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J. Clin. Invest. 92, 2620-2625 (1993).
22. Hyer, S.L., Sharp, P.S., Brooks, R.A., Burrin, J.M. & Kohner, E.M. A two-year follow-up study of serum insulinlike growth factor-I in diabetics with retinopathy. Metabolism 38, 586-589 (1989).
23. Dills, D.G., Moss, S.E., Klein, R., Klein, B.E. & Davis, M. Is insulinlike growth factor I associated with diabetic retinopathy? Diabetes 39, 191-195 (1990).
24. Dills, D.G., Moss, S.E., Klein, R. & Klein, B.E. Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes. Diabetes 40, 1725-1730 (1991).
25. Smith, L.E. et al. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35, 101-111 (1994).
26. Hayry, P. et al. Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat. FASEB J. 9, 1336-1344 (1995).
27. Pietrzkowski, Z., Wernicke, D., Porcu, P., lameson, B.A. & Baserga, R. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res. 52, 6447-6451 (1992).
28. Kroll, J. & Waltenberger, J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J. Biol. Chem. 272, 32521-32527 (1997).
29. Pedram, A., Razandi, M., Hu, R.M. & Levin, E.R. Astrocyte progression from G1 to S phase of the cell cycle depends upon multiple protein interaction. J. Biol. Chem. 273, 13966-13972 (1998).
30. Abedi, H. & Zachary, I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J. Biol. Chem. 272, 15442-15451 (1997).
31. Parenti, A. et al. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase 1/2 activation in postcapillary endothelium. J. Biol. Chem. 273, 4220-4226 (1998).
32. Seger, R. & Krebs, E.G. The MAPK signaling cascade. Faseb. J. 9, 726-735 (1995).
33. Pedram, A., Razandi, M., Hu, R.M. & Levin, E.R. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J. Biol. Chem. 272, 17097-17103 (1997).
34. Alessi, D.R., Cuenda, A., Cohen, P., Dudley, D.T. & Saltiel, A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 27489-27494 (1995).
35. Baserga, R., Hongo, A., Rubini, M., Prisco, M. & Valentinis, B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta 1332, F105-126 (1997).
36. King, G.L., Goodman, A.D., Buzney, S., Moses, A. & Kahn, C.R. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J. Clin. Invest. 75, 1028-1036 (1985).
37. Grant, M.B., Caballero, S. & Millard, W.J. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul. Pept. 48, 267-278 (1993).
38. Graves, J.D., Campbell, J.S. & Krebs, E.G. Protein serine/threonine kinases of the MAPK cascade. Ann. NY Acad. Sci. 766, 320-343 (1995).
39. Klemke, R.L. et al. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol. 137, 481-492 (1997).
40. Punglia, R.S. et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 46, 1619-1626 (1997).
41. The diabetes control and complications trial. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol. 113, 36-51 (1995).
42. Dahl-Jorgensen, K., Brinchmann-Hansen, O., Hanssen, K.F., Sandvik, L. & Aagenaes, O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study Br. Med. J. (Clin. Res. Ed.) 290, 811-815 (1985).
43. Chantelau, E. & Kohner, E.M. Why some cases of retinopathy worsen when diabetic control improves. Br. Med. J. 315, 1105-1106 (1997).
44. Hanssen, K.F., Dahl-Jorgensen, K. & Brinchmann-Hansen, O. The influence of strict control on diabetic complications. Acta Endocrinol. Suppl. (Copenh) 272, 57-60 (1985).
45. Diabetes control and complications trial research group. Progression of retinopathy with intensive versus conventional treatment in the diabetes control and complications trial. Ophthalmology 102, 647-661 (1995).
46. Diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986 (1993).
47. Moskalets, E., Galstyan, C., Starostina, E., Antsiferov, M. & Chantelau, E. Association of blindness to intensification of glycemic control in insulin-dependent diabetes mellitus. J. Diabetes Complications 8, 45-50 (1994).
48. Chantelau, E., Eggert, H., Seppel, T., Schonau, E. & Althaus, C. Elevation of serum IGF-I precedes proliferative diabetic retinopathy in Mauriac's syndrome. Br. J. Ophthalmol. 81, 169-170 (1997).
49. Hammes, H.P., Lin, J., Bretzel, R.G., Brownlee, M. & Breier, G. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 47, 401-406 (1998).
50. Holly, J.M., Amiel, S.A., Sandhu, R.R., Rees, L.H. & Wass, J.A. The role of growth hormone in diabetes mellitus. J. Endocrinol. 118, 353-364 (1988).
51. D'Amato, R., Wesolowski, E. & Smith, L.E. Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse. Microvasc. Res. 46, 135-142 (1993).
52. Capetandes, A. & Gerritsen, M.E. Simplified methods for consistent and selective culture of bovine retinal endothelial cells and pericytes. Invest. Ophthalmol. Vis. Sci. 31, 1738-1744 (1990).
53. Bischoff, J., Brasel, C., Kraling, B. & Vranovska, K. E-selectin is upregulated in proliferating endothelial cells in vitro. Microcirculation 4, 279-287 (1997).
54. Zhang, B., Tavare, J.M., Ellis, L. & Roth, R.A. The regulatory role of known tyrosine autophosphorylation sites of the insulin receptor kinase domain. An assessment by replacement with neutral and negatively charged amino acids. J. Biol. Chem. 266, 990-996 (1991).